Glaucoma Study Re-commences

Seeing Machines Limited
09 November 2006






9th November 2006

                            Seeing Machines Limited

                      ('Seeing Machines' or the 'Company')


                      GLAUCOMA CLINICAL STUDY RE-COMMENCES



Seeing Machines (AIM: SEE), a leading developer of advanced computer based
imaging software systems, announces today the commencement of the next phase of
the second clinical study (CT2b) for its glaucoma testing device, Truefield, as
foreshadowed in the announcement of 30 August 2006 headed 'Glaucoma Project
Clinical Study Results'.  CT2b will commence on 20 November 2006 and will
involve 160 patients in a clinical setting at the Canberra Eye Hospital,
Australia.



The commencement of this phase of the study follows the successful completion of
two scientific studies T13 and T14 at the Canberra Eye Hospital in September
and October.  These studies confirmed the results of the earlier CT1 study which
showed that the device:

  • successfully detects the loss of visual field associated with glaucoma;
    and
  • successfully differentiates between those patients with visual field loss
    and those without, thus providing the basis for a reliable and accurate
    diagnostic instrument.

The two scientific studies also highlighted that the expected improvements in
the performance of the technology since the CT1 study had been achieved.



Commenting on the scientific study results Nick Cerneaz, CEO of Seeing Machines
said: 'These results are very positive and enable us to move forward with our
plans for the introduction of the device, firstly with the commencement of the
next phase of the clinical study, but also all of the other activities needed to
bring the device to market.  This device, TrueField, will be the world's first
non-contact objective test for glaucoma, testing both eyes in 4 minutes.  These
are very significant advantages over existing glaucoma diagnostic devices on the
market today and we have every reason to be confident about the ultimate
commercial success of TrueField.  Our aim, which we are pursuing aggressively,
is to launch the device during calendar year 2007.  We are very grateful for the
work of our partners at the Australian National University led by Dr Ted Maddess
and Dr Andrew James and the support we receive from the Canberra Eye Hospital.
I would also like to acknowledge the work of our own very dedicated staff and
also the financial support we receive for the project from the Australian
Government's Commercial Ready Program'.





--- ENDS ---



Enquiries:
Seeing Machines Limited     Insinger de Beaufort       Parkgreen Communications
Nick Cerneaz, CEO           Simon Fox                  Victoria Thomas
[phone]         [phone]       [phone]
www.seeingmachines.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange